Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer have?
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer has 170 citations in the OpenAlex counts ScholarIQ stores.
When was Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer published?
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer has 2018 year in the ScholarIQ index.
What is the open-access status of Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer?
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer has hybrid oa status in the ScholarIQ index.
What is the DOI of Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer?
The DOI for Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer is on the source record.
What is the PMID of Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer?
The PMID for Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer is on the source record.
What is the OpenAlex record for Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer?
The OpenAlex for Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer is on the source record.